NurExone Biologic
Business Services · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Minus 1 Entry Ground Floor of Building B...Phone Number
+972524803034Website
www.nurexone.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About NurExone Biologic
NurExone is a biotechnology company focused on developing innovative exosome-based therapies for acute spinal cord injury and glaucoma, addressing significant unmet medical needs in these areas. Their ExoTherapy platform utilizes nanosized extracellular vesicles to deliver therapeutic compounds, promoting regeneration and recovery in damaged tissues. With a commitment to minimal invasiveness and effective drug delivery, NurExone aims to revolutionize treatment options for patients. The company is positioned to tap into multi-billion dollar global markets, with a dedicated team and proprietary technology driving their research and development efforts.Explore more
NurExone Biologic Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NurExone Biologic your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when NurExone Biologic launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on NurExone Biologic recently announced quarterly report
Check if NurExone Biologic has recently received funding, and reach out quickly before it becomes old news!
NurExone Biologic, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if NurExone Biologic is spiking on competitors!
Click to see if NurExone Biologic had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at NurExone Biologic
Funding: Get notified immidiatlly once NurExone Biologic has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
NurExone Biologic is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
NurExone Biologic is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about NurExone Biologic.
NurExone Biologic financials insights
Gather financial insights about NurExone Biologic, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$148K
2026
Stock/Share Issuance
$280K
NurExone Biologic Tech Stack
A closer look at the technologies used by NurExone Biologic
See more technologies
Most Recent Scoops
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Funding
Funding
Left Company
Executive Move
Executive Moves, Left Company
NurExone Biologic News & Media
NurExone Announces Closing of C$1,066,078 Private Placement
TORONTO, and HAIFA, Israel, Aug. 21, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that it has closed a non-brokered private placement of 1,938,326 units (“Units”) at a price of C$0.55 per Unit for aggregate gross proceeds of approximately C$1,066,078.02 (the “Offering”), subject to final acceptance of the TSX Venture ExchangeNurExone Reports New Preclinical Tissue-Analysis Data Supporting Potential Neuroprotective Effect of ExoPTEN in Acute Spinal Cord Injury Animal Model
Tissue analysis showed significantly higher numbers of myelin-positive cells in ExoPTEN-treated animals compared with controls, providing additional preclinical biological support for previously reported functional recovery Tissue analysis showed significantly higher numbers of myelin-positive cells in ExoPTEN-treated animals compared with controls, providing additional preclinical biological support for previously reported functional recoveryNurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
The Signed MOU Targets Initial GMP Exosome Batches in H1 2027 to Support NurExone’s Clinical Pipeline and Planned Commercial Production The Signed MOU Targets Initial GMP Exosome Batches in H1 2027 to Support NurExone’s Clinical Pipeline and Planned Commercial ProductionNurExone Launches Bioprocess Optimization Initiative to Support Commercial and Clinical Readiness
TORONTO and HAIFA, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF, FSE: J90) (“NurExone” or the “Company”), a biotechnology company developing exosome-based regenerative therapies, today announced a bioprocess optimization initiative intended to support the manufacturing infrastructure for its therapeutic pipeline and commercial exosome activities.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NurExone Biologic
Sign Up For FreeTo access detailed company insights
NurExone is a biotechnology company focused on developing innovative exosome-based therapies for acute spinal cord injury and glaucoma, addressing significant unmet medical needs in these areas. Their ExoTherapy platform utilizes nanosized extracellular vesicles to deliver therapeutic compounds, promoting regeneration and recovery in damaged tissue... Read More
